- Advanced search
- Immuno Portal
- Malaria Portal
Ligand id: 488
View more information in the IUPHAR Pharmacology Education Project: tamsulosin
Molecular properties generated using the CDK
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Used in the symptomatic relief of benign prostatic hyperplasia.
A 2015 report indicates that tamsulosin increases expulsion of larger (>10mm) kidney stones  in a double-blind, placebo-controlled, randomized, multicenter clinical trial. This result suggests that terazosin and doxazosin, which belong to the same drug class, may provide the same effect.
|Mechanism Of Action and Pharmacodynamic Effects|
|Selective antagonist for α1A- and α1D-adrenoceptors in the prostate, prostatic capsule, prostatic uretha and bladder neck causing relaxation of smooth muscles and therefore decreasing urinary outflow resistance in men.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)